Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Histopathological correlation of diffusion basis spectrum imaging metrics of a biopsy-proven inflammatory demyelinating brain lesion: A brief report.

Shirani A, Sun P, Schmidt RE, Trinkaus K, Naismith RT, Song SK, Cross AH.

Mult Scler. 2018 Jul 1:1352458518786072. doi: 10.1177/1352458518786072. [Epub ahead of print]

PMID:
29992856
2.

A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Shirani A, Wu GF, Giannini C, Cross AH.

BMJ Case Rep. 2018 Jun 28;2018. pii: bcr-2018-225318. doi: 10.1136/bcr-2018-225318.

PMID:
29954769
3.

Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota.

Cignarella F, Cantoni C, Ghezzi L, Salter A, Dorsett Y, Chen L, Phillips D, Weinstock GM, Fontana L, Cross AH, Zhou Y, Piccio L.

Cell Metab. 2018 Jun 5;27(6):1222-1235.e6. doi: 10.1016/j.cmet.2018.05.006.

PMID:
29874567
4.

Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review.

Evans E, Piccio L, Cross AH.

JAMA Neurol. 2018 Apr 23. doi: 10.1001/jamaneurol.2018.0611. [Epub ahead of print]

PMID:
29710293
5.

Effectiveness of alternative dose fingolimod for multiple sclerosis.

Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I.

Neurol Clin Pract. 2018 Apr;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.

PMID:
29708225
6.

Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Ciotti JR, Cross AH.

Curr Treat Options Neurol. 2018 Apr 7;20(5):12. doi: 10.1007/s11940-018-0496-3. Review.

PMID:
29627873
7.

Refining the use of MRI to predict multiple sclerosis.

Cross AH, Naismith RT.

Lancet Neurol. 2018 Feb;17(2):105-106. doi: 10.1016/S1474-4422(17)30459-3. Epub 2017 Dec 21. No abstract available.

PMID:
29275978
8.

Intensity ratio to improve black hole assessment in multiple sclerosis.

Adusumilli G, Trinkaus K, Sun P, Lancia S, Viox JD, Wen J, Naismith RT, Cross AH.

Mult Scler Relat Disord. 2018 Jan;19:140-147. doi: 10.1016/j.msard.2017.11.020. Epub 2017 Dec 2.

PMID:
29223871
9.

Limbic system damage in MS: MRI assessment and correlations with clinical testing.

Wen J, Yablonskiy DA, Salter A, Cross AH.

PLoS One. 2017 Nov 9;12(11):e0187915. doi: 10.1371/journal.pone.0187915. eCollection 2017.

10.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

PMID:
29093070
11.

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.

Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT.

Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357. [Epub ahead of print]

PMID:
28766993
12.

Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.

Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L.

Mult Scler. 2018 May;24(6):728-738. doi: 10.1177/1352458517707069. Epub 2017 May 8.

PMID:
28480794
13.

Speaking out about gender imbalance in invited speakers improves diversity.

Klein RS, Voskuhl R, Segal BM, Dittel BN, Lane TE, Bethea JR, Carson MJ, Colton C, Rosi S, Anderson A, Piccio L, Goverman JM, Benveniste EN, Brown MA, Tiwari-Woodruff SK, Harris TH, Cross AH.

Nat Immunol. 2017 Apr 18;18(5):475-478. doi: 10.1038/ni.3707. No abstract available.

14.

Diffusion MRI quantifies early axonal loss in the presence of nerve swelling.

Lin TH, Chiang CW, Perez-Torres CJ, Sun P, Wallendorf M, Schmidt RE, Cross AH, Song SK.

J Neuroinflammation. 2017 Apr 7;14(1):78. doi: 10.1186/s12974-017-0852-3.

15.

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study.

Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 24;4(3):e339. doi: 10.1212/NXI.0000000000000339. eCollection 2017 May.

16.

Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein.

Lyons JA, Riter MM, Almatrook AM, Ramsbottom MJ, Cross AH.

J Neuroimmunol. 2016 Nov 15;300:66-73. doi: 10.1016/j.jneuroim.2016.06.006. Epub 2016 Jun 24.

17.

"A new imaging modality to non-invasively assess multiple sclerosis pathology".

Cross AH, Song SK.

J Neuroimmunol. 2017 Mar 15;304:81-85. doi: 10.1016/j.jneuroim.2016.10.002. Epub 2016 Oct 8. Review.

18.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

19.

A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.

Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross AH, Morgan TE, Wei M, Paul F, Bock M, Longo VD.

Cell Rep. 2016 Jun 7;15(10):2136-2146. doi: 10.1016/j.celrep.2016.05.009. Epub 2016 May 26.

20.

On the relationship between cellular and hemodynamic properties of the human brain cortex throughout adult lifespan.

Zhao Y, Wen J, Cross AH, Yablonskiy DA.

Neuroimage. 2016 Jun;133:417-429. doi: 10.1016/j.neuroimage.2016.03.022. Epub 2016 Mar 17.

21.

Simultaneous multi-angular relaxometry of tissue with MRI (SMART MRI): Theoretical background and proof of concept.

Sukstanskii AL, Wen J, Cross AH, Yablonskiy DA.

Magn Reson Med. 2017 Mar;77(3):1296-1306. doi: 10.1002/mrm.26176. Epub 2016 Mar 15.

PMID:
26991525
22.

Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity.

Longbrake EE, Cross AH.

JAMA Neurol. 2016 Feb;73(2):219-25. doi: 10.1001/jamaneurol.2015.3977. Review.

PMID:
26720195
23.

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.

Longbrake EE, Cross AH, Salter A.

Mult Scler J Exp Transl Clin. 2016 Jan-Dec;2. doi: 10.1177/2055217316677868. Epub 2016 Nov 1.

24.

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures.

Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Dec 24;1:2055217315623800. doi: 10.1177/2055217315623800. eCollection 2015 Jan-Dec.

25.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

PMID:
26621682
26.

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.

Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1. pii: 2055217315596994. Epub 2015 Jul 31.

27.

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L.

Mult Scler. 2016 Jul;22(8):1061-1070. doi: 10.1177/1352458515608961. Epub 2015 Oct 12.

28.

Detection of cortical lesions in multiple sclerosis: A new imaging approach.

Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Sep 24;1:2055217315606465. doi: 10.1177/2055217315606465. eCollection 2015 Jan-Dec.

29.

Enhancing our understanding of white matter changes in early multiple sclerosis.

Naismith RT, Cross AH.

Brain. 2015 Sep;138(Pt 9):2465-6. doi: 10.1093/brain/awv196. No abstract available.

PMID:
26304148
30.

Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.

Wang Y, Sun P, Wang Q, Trinkaus K, Schmidt RE, Naismith RT, Cross AH, Song SK.

Brain. 2015 May;138(Pt 5):1223-38. doi: 10.1093/brain/awv046. Epub 2015 Feb 26.

31.

TREM2 regulates microglial cell activation in response to demyelination in vivo.

Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L.

Acta Neuropathol. 2015 Mar;129(3):429-47. doi: 10.1007/s00401-015-1388-1. Epub 2015 Jan 29.

32.

Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.

Wen J, Yablonskiy DA, Luo J, Lancia S, Hildebolt C, Cross AH.

Neuroimage Clin. 2015 Aug 18;9:164-75. doi: 10.1016/j.nicl.2015.08.003. eCollection 2015.

33.

Dimethyl fumarate associated lymphopenia in clinical practice.

Longbrake EE, Cross AH.

Mult Scler. 2015 May;21(6):796-7. doi: 10.1177/1352458514559299. Epub 2014 Nov 28. No abstract available.

34.

Antisense therapy: potential tool to reduce activity in MS via protein expression inhibition.

Naismith RT, Cross AH.

Neurology. 2014 Nov 11;83(20):1776-7. doi: 10.1212/WNL.0000000000000927. Epub 2014 Sep 19. No abstract available.

PMID:
25239837
35.

Quantifying white matter tract diffusion parameters in the presence of increased extra-fiber cellularity and vasogenic edema.

Chiang CW, Wang Y, Sun P, Lin TH, Trinkaus K, Cross AH, Song SK.

Neuroimage. 2014 Nov 1;101:310-9. doi: 10.1016/j.neuroimage.2014.06.064. Epub 2014 Jul 11.

36.

Axonal transport rate decreased at the onset of optic neuritis in EAE mice.

Lin TH, Kim JH, Perez-Torres C, Chiang CW, Trinkaus K, Cross AH, Song SK.

Neuroimage. 2014 Oct 15;100:244-53. doi: 10.1016/j.neuroimage.2014.06.009. Epub 2014 Jun 14.

37.

Active and progressive: a new duality of MS classification.

Cross AH, Wingerchuk DM, Weinshenker BG.

Neurology. 2014 Jul 15;83(3):206-7. doi: 10.1212/WNL.0000000000000601. Epub 2014 Jun 13. No abstract available.

PMID:
24928117
38.

Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.

Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, Piccio L, Schmidt RE, Cross AH, Crosby SD, Klein RS.

J Clin Invest. 2014 Jun;124(6):2571-84. doi: 10.1172/JCI73408. Epub 2014 May 8.

39.

Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis.

Shin S, Walz KA, Archambault AS, Sim J, Bollman BP, Koenigsknecht-Talboo J, Cross AH, Holtzman DM, Wu GF.

J Neuroimmunol. 2014 Jun 15;271(1-2):8-17. doi: 10.1016/j.jneuroim.2014.03.010. Epub 2014 Mar 29.

40.

Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis.

Lin TH, Spees WM, Chiang CW, Trinkaus K, Cross AH, Song SK.

Neurobiol Dis. 2014 Jul;67:1-8. doi: 10.1016/j.nbd.2014.02.007. Epub 2014 Mar 13.

41.

On the role of physiological fluctuations in quantitative gradient echo MRI: implications for GEPCI, QSM, and SWI.

Wen J, Cross AH, Yablonskiy DA.

Magn Reson Med. 2015 Jan;73(1):195-203. doi: 10.1002/mrm.25114. Epub 2014 Jan 30.

42.

Established and novel disease-modifying treatments in multiple sclerosis.

Cross AH, Naismith RT.

J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11. Review.

43.

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E.

Mult Scler. 2013 Dec;19(14):1938-42. doi: 10.1177/1352458513485654.

PMID:
24277735
44.

Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1.

Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, Della Bianca V, Bach SD, Scarpini E, Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, Constantin G.

J Immunol. 2013 Dec 1;191(11):5489-500. doi: 10.4049/jimmunol.1301235. Epub 2013 Oct 30.

45.

Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Longbrake EE, Parks BJ, Cross AH.

Curr Neurol Neurosci Rep. 2013 Nov;13(11):390. doi: 10.1007/s11910-013-0390-z. Review.

46.

Comment: assessing humoral immunocompetence after alemtuzumab treatment in MS.

Cross AH, Klein RS.

Neurology. 2013 Sep 3;81(10):875. doi: 10.1212/WNL.0b013e3182a352c6. Epub 2013 Aug 7. No abstract available.

PMID:
23925764
47.

Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis.

Querol L, Clark PL, Bailey MA, Cotsapas C, Cross AH, Hafler DA, Kleinstein SH, Lee JY, Yaari G, Willis SN, O'Connor KC.

Neurology. 2013 Sep 10;81(11):956-63. doi: 10.1212/WNL.0b013e3182a43b48. Epub 2013 Aug 6.

48.

Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions.

Luo J, Yablonskiy DA, Hildebolt CF, Lancia S, Cross AH.

Mult Scler. 2014 Mar;20(3):349-55. doi: 10.1177/1352458513495935. Epub 2013 Jul 8.

49.

Genetic risk variants in African Americans with multiple sclerosis.

Isobe N, Gourraud PA, Harbo HF, Caillier SJ, Santaniello A, Khankhanian P, Maiers M, Spellman S, Cereb N, Yang S, Pando MJ, Piccio L, Cross AH, De Jager PL, Cree BA, Hauser SL, Oksenberg JR.

Neurology. 2013 Jul 16;81(3):219-27. doi: 10.1212/WNL.0b013e31829bfe2f. Epub 2013 Jun 14.

50.

Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease.

Naismith RT, Xu J, Klawiter EC, Lancia S, Tutlam NT, Wagner JM, Qian P, Trinkaus K, Song SK, Cross AH.

Neurology. 2013 Jun 11;80(24):2201-9. doi: 10.1212/WNL.0b013e318296e8f1. Epub 2013 May 10.

Supplemental Content

Loading ...
Support Center